Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Bright Giant GmbH and Agilent Technologies Announce Collaboration: Innovation for Identification

Bright Giant GmbH and Agilent Technologies are excited to announce their new product development collaboration, designed to enhance non-targeted metabolomics workflows using AI-based methods and empower scientists to make novel, impactful discoveries.

Latest Aithority Insights: AiThority.com to Attend The Character of AI – A Technology Ethics Conference (Virtual)

Bright Giant GmbH and Agilent Technologies announce collaboration to enhance non-targeted metabolomics workflows #BrightGiant #Agilent #massspectrometry #metabolomics #SIRIUSScience

This collaboration aims to combine Bright Giant’s expertise in artificial intelligence solutions for small molecule research with Agilent’s state-of-the-art mass spectrometry technology. Rapid, fully automated compound identification remains a major bottleneck for the discovery of novel bioactive molecules – in metabolomics, as well as areas such as environmental analysis and pharma. The structural elucidation of these molecules directly facilitates toxicologic and ecologic screenings and plays a crucial part in the discovery of novel drug leads.

Related Posts
1 of 41,164

Top Artificial Intelligence InsightsCould Instances of NLP Bias Derail AI?

Paramount for the success of modern analytical chemistry research, is the interplay between data generation and data interpretation. “By combining the high data quality of Agilent’s modern instrumentation with our decade-long research on AI methods for small molecule annotation, we will pave the way towards expanding the realm of chemical knowledge beyond what is currently possible,” said Prof. Sebastian Böcker, professor for bioinformatics at the Friedrich Schiller University in Jena and Co-Founder of Bright Giant.

“Agilent recognizes the growing desire for non-targeted metabolomics, environmental analysis, and pharma solutions,” said Jennifer Gushue, associate vice president of MS Marketing, Mass Spectrometry Division at Agilent. “The Böcker Lab have proven best-in-class tools for structure elucidation with mass spec data, and Agilent has collaborated with them for over a decade. We are excited to further strengthen our commitment to state-of-the-art algorithmic solutions, to continuously provide our customers with the highest level of analytic tools.”

AI ML in Marketing: AI and Big Data Analysis Used to Find Brands’ Emotional Connection

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.